Key Summary Current knowledge Inflammatory bowel disease may be associated with an increased risk of various infections. Certain inflammatory bowel disease therapies may predispose to an increased risk of infections (e.g., anti tumour necrosis factor and tuberculosis, tofacitinib and herpes zoster). The effect of inflammatory bowel disease and inflammatory bowel disease therapies on coronavirus disease infection and outcomes is unclear. What are the new findings? In this meta‐analysis, we found that the risk of coronavirus disease in patients with inflammatory bowel disease is similar to the general population. The risk of coronavirus disease does not seem to be affected by the underlying type of inflammatory bowel disease, that is, Crohn’s disease or ulcerative colitis. The risk of adverse outcomes in inflammatory bowel disease is more in patients receiving steroids and 5‐aminosalicylates. Biological agent use seems to be protective against adverse outcomes of coronavirus disease in inflammatory bowel disease patients.
【저자키워드】 coronavirus, SARS‐CoV‐2, ulcerative colitis, Crohn's disease,